| Identification | More | [Name]
10-Hydroxycamptothecin | [CAS]
64439-81-2 | [Synonyms]
10-HYDROXYCAMPTOTHECIN ACETATE
10-HYDROXYCAMPTOTHECIN ACETATE SALT
7-ETHYL-10-HYDROXY CAMPTHOTECIN
Hydroxy Camptothecine
77-Ethyl-10-hydroxy campthotecin
(20S)-7-Ethyl-10-Hydroxycamptothecin
10-Hydroxycamp-totecin
7ETHYHYDROXYCAMPTOTHECIN
10-Hydroxyl-20(S)-Camptothecin
(+/-)-4-Ethyl-4,9-dihydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(20S)-4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione | [EINECS(EC#)]
613-598-9 | [Molecular Formula]
C22H20N2O7 | [MDL Number]
MFCD00274425 | [Molecular Weight]
424.4 | [MOL File]
64439-81-2.mol |
| Chemical Properties | Back Directory | [Melting point ]
230-237°C | [Boiling point ]
820.7±65.0 °C(Predicted) | [density ]
1.60 | [storage temp. ]
−20°C
| [solubility ]
DMSO: ≥ 37.5 mg/mL (102.92 mM) | [form ]
Pale yellow powder | [pka]
8.93±0.40(Predicted) | [color ]
Yellow | [InChI]
InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3 | [InChIKey]
LCZZWLIDINBPRC-FQEVSTJZSA-N | [SMILES]
N1C2C(=CC(O)=CC=2)C=C2CN3C(C=12)=CC1C(CC)(O)C(=O)OCC=1C3=O | [CAS DataBase Reference]
64439-81-2(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
3
| [RTECS ]
UQ0491000 |
| Hazard Information | Back Directory | [Chemical Properties]
mp 268-270°C loss on drying <1% | [Uses]
therapeutic effects for liver cancer, stomach, and neck cancer and leukemia. | [Uses]
Topoisomerase inhibitor | [storage]
Store at -20°C |
| Questions And Answer | Back Directory | [Structure]
The 10-Hydroxycamptothecin (10-HCPT) contains a lactone ring structure, which is key in keeping its anticancer activity. When the ring is hydrolyzed and opened, the activity of the 10-HCPT will be significantly reduced or inactivated. The stability of the ring structure of the lactone in the 10-HCPT is strongly related to the pH value. The structure of the lactone ring will be a closed loop when the pH value is less than 5, and the activity of 10-HCPT can be enhanced. When the pH value exceeds 7.4, the lactone ring will be broken, and the hydroxyl lactone will be inactivated. Accordingly, 10-HCPT has poor stability and low aqueous solubility. Nevertheless, previous reports have indicated that the water solubility and stability of 10-HCPT can be improved by complexation with liposomes. Furthermore, the delivery system of the liposome can increase the treatment efficacy of drugs by decreasing renal clearance and prolonging blood circulation[2]. |
|
|